Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

about

Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?

P2860

Q54977224-5520CC4D-EE71-4A4E-9207-660D9C3F397A

P2860

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q42701803

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@en

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@nl

type

Item

label

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@en

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@nl

prefLabel

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@en

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@nl

P1476

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

@en

P2093

David Muram

http://www.w3.org/2001/XMLSchema#string

Douglas E Schlichting

http://www.w3.org/2001/XMLSchema#string

Jahangir Alam

http://www.w3.org/2001/XMLSchema#string

John Bradley

http://www.w3.org/2001/XMLSchema#string

Roy Fleischmann

http://www.w3.org/2001/XMLSchema#string

Vipin Arora

http://www.w3.org/2001/XMLSchema#string

P2860

Long term safety of etanercept in elderly subjects with rheumatic diseases.

Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

The safety of anti-TNF agents in the elderly.

P304

e000546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2017-000546

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josef S Smolen

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29071120

http://www.w3.org/2001/XMLSchema#string

P932

5640108

http://www.w3.org/2001/XMLSchema#string

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

about

P2860

P2860

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932